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18. Quantitation of Circulating Fibrinogen Breakdown Products
in Intravasctrlar Clotting
H. C. Hn"l<en, N. Fernls, A. HENsrn, FI. ScHnrlvtn and E. A. LoEucrn
The case which prompted the investigation reported here concern es a 3l year
old multipara who developed a pecuTiar defibrination syndrome after having
given birth to twins who died of asphyxia during delivery.
Twenty-four hours after delivery the fibrinogen contenr of the plasma, esti-
mated according to clauss (1), appeared to be 20 mgo/0, but a rather firm clot
formed after longer incubation with thrombin. Moreover, the patient did not
bleed, and the thrombelastogram did not show any of the signs typical of a low
fibrinogen content.
This case brought out strongly a discrepancy that is rather often seen and
more often suspected in the laboratory, viz. the discrepancy between the
fibrinogen contenr measured by the clauss method and the amount of fibrin
apparently formed by the same plasma.
It is known rhat many kinds of fibrin- and fibrinogen-breakdown products
are formed during intravascular clotting. Proteolysis accompanying intravascular
clotting may cause fibrinogen to lose its clottability and immunological proper-
ties. Some of the products formed may gain the ability to inhibit thrombin
action, polymerization of fibrin, or srages in the prephase of blood-clotting
(2-10). Fibrin may undergo a similar breakdown. For all practical purposes in
the present paper this heterogeneous group of products can be divided into three
sub-groups, viz.:
a) unaltered fibrinogen
b) antifibrinogen-precipitabie but unclottable material
c) material inhibiting the formation rate of a fibrin clot.
ve attempted to estimate rhe relative amounts and half-life times of the
fibrin(ogen) derivatives in our patient. The antifibrinogen positive material in the
serum and plasma can be estimated on the basis of immunologic reactions. Fer-
reira et aI. (1,1,, 12) have worked our a semi-quanrirative method which was not,
however, sensitive enough to suit our purposes. Schwick (13) has developed
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a method by which the amounr of precipitate is measured nephelometrically' We
ninp*a a method b;; ;" u i'i"tipi" developed by Mancini et al' 
(14)
and also independently by Riimke (15)'
I n t h i s m e t h o d , t t , . g . t i n w h i c h t h . , n - p l . d i f f u s e s , a | r e a d y c o n t a i n s t h e
antibody, in this case rabbit anti-human fibrinogen'
The immuni zationscheme was suggested to us by Dr' W' Hijmans (Department
of Rheumatology, University Hospital, Leyden)' With an interval of 1 week'
we gave 3 i.m. injections of 100 mg human fibrinogen (fraction 1-4' kindly
supplied by Dr. eto.rriack; with 1 -i*o{ F...rrrd,s adjuvans. Jhlee weeks after the
f"rr^ i.rt. injectio.t, in...uring doses of aium-precipitated fibrin"g::^-"it i:l:l
i.v. at 2- or 3-da,y intervals (twice 25 mg; twice 50 mg; twice 100 mg; twtce
2 0 0 m g ) . T e n d a y s a f t e r t h e l a s t i . v . i n j e c t i o n t h e r a b b i t s w e r e b l e d . T h e s e r u m
was incubated with one-tenrh its volume of normal human serum to precipitate
,ron-rp".ifi. antibodies, centrifuged, and stored in 1 ml portions at' 
-20" ' The
g e l c o t r i s t . d o f O ' 8 0 / o ' a g a r r r a " s o l u t i o n c o n t a i n i n g 0 ' 3 6 M N 1 C l ' 1 5 m M K C l '
; *u K_Na phosphate"buffer (pH 7.4), and 10/oo sodium azide. Before soiidi-
fication, 0.80i0 (v.v.) of anti-human fibrinogen rabbit l":itttiT was added' and
t2 m\ of the mixrure poured out in a plastic Petri dish_ (diameter 8'5 cm)'
Holes with a diameter of 3 mm -.r. prrrrihed out in the gel' and O.O1 ml of the
Fig. 1. A plate after incubation'
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solution to be tested was pipeted into them. After 3 days incubadon at 37a
the dishes were photographed on a one-to-one scale, and the diameter of the
precipitation rings was measured. The square of the diameter of course is
proportional to the surface area.
The antigen diffuses out in the gel, and after 1-3 days of incubation at 37o
a precipitation ring shows up. The area enclosed by this ring is proportional to
the amount of antigen brought into the well. Fig. 1 shows a gel-plate after
incubation. Fig. 2 shows the relationship berween the area and the amounr of
antigen added with human fibrinogen as the antigen. The standard error was less
than 3olo.
Squoreof diometerof precipitotioa ring (mm)2
Fig. 2. The calibration curve.
It is interesting to note that with this method one precipitation ring always
shows up when a mixture of antifibrinogen-positive materials is present, although
it is known that fibrinogen and its breakdown products differ in their antigenic
and diffusion behaviour. Because of these differences we can only express the
quantity of antifibrinogen-positive material as the equivalent amount of fibrin-
ogen giving an equal precipitation ring.
Fibrinogen itself was measured in 3 ways:
1. As the clotting of the diluted plasma with a standard amount of thrombin
(Clauss method).
To 0.1 ml of an appropriate dilution (1 in 10 for normal plasma ranges) of
the plasma sample in Michaelis buffer (pH7.4),0.1 ml of a thrombin solution
(64 NIH u/ml) is added at zero time. The reaction is carried out at 37o, the
moment of clotting is assessed with a Kolle hook.
2. Gravimetrically, as the amounr of fibrin recovered after clotting of the
prasma.
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3. As the amor.rnr of antifibrinogen-positive rnatertal in the plasma minus 
the
- -u*ourr  
of antifibrinogen-po;itive m'terial in the serum' with the assum-
tions that (a) no ffin.ur., amount of antifibrinogen-positiv material is
ok.r, .rp by tt 
" 
.loi u.rd (b) that this material has a similar reacrivity as
fibrinogen.
Of these methods' the first is sensitive to
last two are not. A fairly good agreement
methods.
Fig. 3 shows the pertinent data in our patient'
inhibiting substances, vrhereas the
was found between the last two
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o
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o
C
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DoYs ofter delivery
Fie. 3. The data of fibrinogen estimations.obtained in the case reported' 
o--o Antifibrinogen-
poi i r i r r "  mater ia l  in p lasma, A---A ant i f ibr inogen-posi t ive mater ia l  in s.erum 
(on a scale 10X
tl.,e ,crle o,f the y-axis) , -'- - -- - antifibrinog.rr-pJririrr" material in plasma 
minus the anti-
iuri'.g*-p.rir;,," ','ur..iul ; ';.j;';-:;Tbil;'n "o"'""' of the plasma s found with
Assumingtha tno fur ther in t ravascu la rpro teo lys isoccur redaf te rde l i very ,
we could esrimate the half-life time of the antifibrinogen-positive but unclottable
material from the esrimation of this material in the serum of the patient' 
This
value proved to be /g fr, -tri"fr is equal to the lower limit of the half-life 
of
normal fibrinogen tf el. it should be not6d that the blood was collected 
in a
solution containing BAC6 and Trasylol in order to prevent proteolysis 
after
.r.niprrn.rrrre. (Finil concentrations: EACA 1 mg/ml' Trasylol 1 u/ml)'
To estimate the half-life time of the inhibiting substances, we would first have
to know how these substances act. To understand this action, we would have 
to
know the normal kinetic behaviour of the fibrinogen-thrornbin interaction; and
this we do not yet know in detail' tVe do know' however' that a graph com-
( Pot.nr. B11 447-1618/65 )
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parable to the Lineweaver-Burk plot is obtained when clotting time is plotted
against the inverse of the square of the fibrinogen concenrration (Fig. 5) (21).
By using this plot, the mode of inhibitory action cotrld be assessed; it was
found to be a competitive one (Fig. 6).
Fig. 4. The disappearance rate of the antifibrinogen positive breakdown products. The log of
the concentration of antifibrinogen-positive material in serum, expressed as the equivalent
concentration of normal fibrinogen (in mg/ml) is plotted on the y-axis against time (in days)
' on tne x-axls. 
:a: - .
Fig. 5. The relation between fibrinogen concenrration and clotting time.
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Fig. 6. The mode of inhibition bY
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' Thi, finding is in agreement with the-results of Triantaphyllopoulos (17) but
it undoubtedl! ,"pr.r""nts an oversimplification because we knovr that 
many dif-
i"r"rr. kind, of i.rhibition occur in rh.r. .ur., (9, 18, 19). In our experimental
,"i-,rp, however, the inhibition can for all practical p"1q9:": be described as
being'of a purely competirive type. In competitive inhibition the apparent
"-oin, 
of ,,tbrtrut" pro.rr, (S.) i; related 'o tht real amount present (SJ by
the formula: Sn : ,t:,-- (20). This equation gives the relation between the
1 + I/Kt
amount of fibrinogen -""#"d in the Clauss test (S") and the amount found by
the immunological test or with the gravimetrical method (S')' Since both these'
data areknown, we can find a relatirre measure for the amount of inhibitor (I)
(viz.: I e | -fil.tn* is about the best we can hope to obtain with this kind
of data. The half-life time of the inhibiting substances can now be estimated
(Fig. 7). This value rurns out to be 19 h, which is substantially lower than that
or iUrirrog"n or antifibrinogen-positive material. The inhibitory substances are
probably ih" s-aller -o1..,11"r,^und it is conceivable that these small molecules
iirupp.u, from the circulation more rapidly than the larger ones do. This is
consistenr with the fact that in chronic defibrination we found antifibrinogen-
positive materialin the serum, but no - or Lt least remarkably little - inhibi-
iory u.tion by the Clauss test. our observations are not consistent with the idea
that the e*ist"rr.e of a fibrinogen with altered reactivity is the main cause of the
o//owith inhibitor
inhibitor
isz
oroducts of the thrombin catalysed
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Acta
c1in.
slow fibrinogen conyersion (1.7), because altered fibrinogen would behave as non-
competitively - or incompetitively - inhibited normal fibrinogen and would
have about the same half-life as normal fibrinogen has. Altered fibrinogen may,
of course, be present but it is not detecrable in our tests.
l"r3 *,t".. o1,rl,., u t
Fig' 7' The disappearance rate of thrombin inhibiting breakdown products (see text).
In conclusion,itmay be said that the two-dimensional agar diffusion methods
are valuable for the investigation of the defibrination syndrome, because, to-
gether with the clauss method and the gravimerrical method of fibrinogen
estimation, they enable us to assess the fibrinogen contenr and to get an i-pres-
sion of the relative amounts of antifibrinogen-positive material and thrombin-
inhibiting breakdown producrs.
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